Abstract
‘‘Personalized’’ or precision medicine is a contemporary term applied to the oldest stopgap style of medical practice, reserved for when no one set of rules intended for the masses can be applied to the individual. This tailored approach describes the adjuvant treatment strategy for stage II colon cancer patients. Unlike stage III colon cancer patients, the role of adjuvant chemotherapy for stage II patients is uncertain. Overall, 25–40 % of patients diagnosed with adenocarcinoma of the colon will have stage II disease, which portends a relatively good prognosis, with 5-year overall survival rates ranging from 72 to 85 %. Conversely, up to 25 % of stage II colon cancer patients will develop recurrent disease, and most of these patients will die as a result of their recurrence. With treatment en masse, routine administration of FOLFOX-based adjuvant chemotherapy to stage II colon cancer patients does not substantially improve overall survival compared with single-agent 5-fluorouracil. 1 In an effort to better identify and
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
